RARE - Ultragenyx Pharmaceutical Inc.
| Previous Close | 56.36 |
| Open | 56.89 |
| Bid | 0.00 x 1300 |
| Ask | 0.00 x 800 |
| Day's Range | 54.35 - 58.00 |
| 52 Week Range | 35.41 - 74.50 |
| Volume | 328,101 |
| Avg. Volume | 581,306 |
| Market Cap | 3.179B |
| Beta (5Y Monthly) | 2.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Benzinga
The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 15) 10X Genomics Inc (NASDAQ: TXG ) Aimmune Therapeutics ...
- Zacks
Ultragenyx Provides Preliminary Crysvita 2019 Revenues
Ultragenyx (RARE) provides preliminary 2019 revenue numbers and 2020 outlook for Crysvita, along with other pipeline updates.
- Zacks
Ultragenyx's Gene Therapy Positive in Genetic Disorder Study
Shares of Ultragenyx (RARE) rise 23.4% after releasing positive top-line data from the phase I/II study of its gene therapy candidate DTX301 for the treatment of OTC deficiency.
- Benzinga
The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: ...
- Benzinga
Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus
Biotech stocks advanced in the penultimate week of the year, and the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) is on track to end the year with gains in excess of 25%. The previous week saw FDA ...
- Insider Monkey
Do Hedge Funds Love Ultragenyx Pharmaceutical Inc (RARE)?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- GuruFocus.com
Astellas-Audentes Deal Likely to Ignite More Acquisitions
Companies with gene therapy capabilities are becoming more attractive to members of Big Pharma, who are eager to add the technology to their portfolios Continue reading...
- Zacks
Ultragenyx (RARE) Up 13.6% Since Last Earnings Report: Can It Continue?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
Companies Like Ultragenyx Pharmaceutical (NASDAQ:RARE) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- Thomson Reuters StreetEvents
Edited Transcript of RARE earnings conference call or presentation 5-Nov-19 10:00pm GMT
Q3 2019 Ultragenyx Pharmaceutical Inc Earnings Call
- American City Business Journals
After son’s rare disease diagnosis, father finds hope through film festival
A Mission Bay film festival this weekend is aimed at filmmakers and film lovers, but more so at patients, advocates, doctors and researchers dealing with rare diseases.
- Zacks
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q3
Ultragenyx (RARE) reports wider-than-expected loss and misses sales estimates in the third quarter of 2019.
- Zacks
Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of -14.62% and -9.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Ultragenyx (RARE) Expected to Beat Earnings Estimates: Should You Buy?
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Insider Monkey
Were Hedge Funds Right About Dumping Ultragenyx Pharmaceutical Inc (RARE)?
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
- American City Business Journals
These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year
While initial public offerings get most of the splash, public companies also are raking in cash with follow-on offerings. How long will the Wall Street spigot stay open?
- Simply Wall St.
Those Who Purchased Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Three Years Ago Have A 34% Loss To Show For It
For many investors, the main point of stock picking is to generate higher returns than the overall market. But the...
- Zacks
Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA
Ultragenyx (RARE) announces FDA's acceptance of the NDA for UX007 for the treatment of LC-FAOD.
- Zacks
Ultragenyx Gets FDA Approval for Label Expansion of Crysvita
Ultragenyx (RARE) and partner Kyowa Kirin get FDA approval for the label expansion of Crysvita in pediatric patients with X-linked hypophosphatemia.
- GuruFocus.com
Ultragenyx Pharmaceutical Inc (RARE) President & CEO Emil D Kakkis Bought $218,150 of Shares
President & CEO of Ultragenyx Pharmaceutical Inc (30-Year Financial, Insider Trades) Emil D Kakkis (insider trades) bought 5,000 shares of RARE on 09/11/2019 at an average price of $43.63 a share. Continue reading...
- Zacks
Ultragenyx to Submit sBLA for Label Expansion of Crysvita
Ultragenyx (RARE) and partner Kyowa Kirin plan to submit an sBLA to the FDA for the label expansion of Crysvita.
- Zacks
Ultragenyx-GeneTx Get Orphan Drug Status for GTX-102 From FDA
The FDA grants Orphan Drug and Rare Pediatric Disease designations to Ultragenyx (RARE) and partner GeneTx Biotherapeutics' GTX-102 for the treatment of Angelman Syndrome.
- Simply Wall St.
Is Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Trading At A 36% Discount?
Does the September share price for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) reflect what it's really worth? Today...
- Zacks
Ultragenyx (RARE) Down 9.9% Since Last Earnings Report: Can It Rebound?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Ultragenyx (RARE) Focuses on Pipeline Amid Low Revenues
Ultragenyx (RARE) focuses on the development of pipeline candidates. Being a new commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses.
